Loading...
01/09 22:53
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerning factors: a decreased gross margin, increased net loss, and heavy reliance on FDA approval and BARDA contract. The Q&A section indicates management's uncertainty regarding commercialization timelines and reliance on government contracts. Despite a reduction in G&A expenses, the financial strain from a significant net loss and limited revenue diversification suggests a negative outlook. The lack of immediate sales in international markets further compounds these issues. Consequently, the predicted stock price movement over the next two weeks is negative (-2% to -8%).
Research and Development Revenue $5.1 million, reduced from $7.5 million in the second quarter of last year, reflecting anticipated reduced reimbursements under the BARDA Project BioShield contract.
Gross Margin 45.2%, decreased slightly from 46.6% in the second quarter of last year due to a lower percentage of reimbursed expenses under the Project BioShield BARDA contract.
General and Administrative Expenses $4.4 million, significantly reduced from $5.8 million in the second quarter of 2024, primarily due to continued focus on operating efficiencies and the completion of the de novo submission to the FDA.
Net Loss (Quarterly) $7.9 million, compared to a net loss of $2.9 million in the second quarter of 2024, driven by an increase in the fair value of its publicly traded warrant liability of $5.4 million.
Net Loss (6-Month Period) $5.1 million, reduced from $6.1 million for the first 6 months of last year, a reduction of over $1 million.
Cash and Cash Equivalents $10.5 million as of June 30, 2025, up from $5.2 million on December 31, 2024, primarily due to the company completing its financing.
DeepView System: FDA submission for the DeepView System was completed in Q2 2025. The company is planning a U.S. launch of the system, focusing on burn indications.
Market Expansion: Revenue guidance for 2025 is $21.5 million, excluding potential contributions from DeepView System sales in the UK and Australia, which are not expected to be material for 2025.
Financial Position: The company completed a debt financing agreement of up to $15 million, with an initial draw of $8.5 million, and raised $2.7 million in equity financing. Cash on hand at the end of June 2025 was over $10 million, with potential access to an additional $6.5 million of debt.
Cost Management: General and administrative expenses were reduced from $5.8 million in Q2 2024 to $4.4 million in Q2 2025, reflecting a focus on operational efficiencies.
Strategic Shift: The company is focusing on the commercialization of the DeepView System and has submitted a de novo application to the FDA. Additionally, it is progressing with the IPO of its healthcare intellectual property-focused subsidiary, Spectral IP Inc.
Reduced R&D Revenue: The company's research and development revenue decreased from $7.5 million in Q2 2024 to $5.1 million in Q2 2025, reflecting reduced reimbursements under the BARDA Project BioShield contract. This could impact the company's ability to fund future R&D activities.
Decreased Gross Margin: Gross margin dropped slightly from 46.6% in Q2 2024 to 45.2% in Q2 2025, primarily due to a lower percentage of reimbursed expenses under the BARDA contract. This could affect profitability.
Net Loss Increase: The company reported a net loss of $7.9 million in Q2 2025 compared to $2.9 million in Q2 2024, driven by an increase in the fair value of its publicly traded warrant liability. This indicates financial strain.
Dependence on FDA Approval: The company's future funding and commercialization efforts are heavily reliant on FDA approval of its de novo application. Delays or rejection could significantly impact operations and strategic goals.
Reduced General and Administrative Expenses: While G&A expenses were reduced from $5.8 million in Q2 2024 to $4.4 million in Q2 2025, this reduction may limit resources available for operational and strategic initiatives.
BARDA Contract Dependency: The company’s financial performance is closely tied to the BARDA Project BioShield contract. Any changes or reductions in this contract could adversely affect revenue and operations.
Limited Revenue Diversification: Revenue guidance for 2025 does not include material contributions from sales of the DeepView System in the UK or Australia, indicating limited diversification and reliance on U.S. market success.
FDA Submission and Commercialization: The company has completed its de novo application submission to the FDA in Q2 2025 and expects further interactions with the FDA in the coming months. This submission is a critical step towards the commercialization of the DeepView System, with a planned U.S. launch.
Financial Position and Funding: Spectral AI has over $10 million in cash as of June 2025, with potential access to an additional $6.5 million in debt financing and $7 million in equity upon FDA approval. This funding is expected to support the company’s operations and product commercialization efforts for the foreseeable future.
Revenue Guidance for 2025: The company reiterates its revenue guidance of approximately $21.5 million for 2025. This does not include potential contributions from DeepView System sales in the UK or Australia, which are not expected to be material for 2025.
The selected topic was not discussed during the call.
The earnings call highlights several negative factors: reduced revenue guidance, increased dependence on the BARDA contract, rising operating costs, and a net loss increase. Although there are some positive aspects, such as FDA submission progress and positive feedback from international markets, these are overshadowed by the negative financial trends and uncertainties about future revenue and commercialization. The Q&A session further underscores these concerns, with management providing vague responses on critical matters, contributing to a negative sentiment and likely negative stock price reaction.
The earnings call reveals several concerning factors: a decreased gross margin, increased net loss, and heavy reliance on FDA approval and BARDA contract. The Q&A section indicates management's uncertainty regarding commercialization timelines and reliance on government contracts. Despite a reduction in G&A expenses, the financial strain from a significant net loss and limited revenue diversification suggests a negative outlook. The lack of immediate sales in international markets further compounds these issues. Consequently, the predicted stock price movement over the next two weeks is negative (-2% to -8%).
The earnings call presents a mixed picture. Positive aspects include improved financial metrics, reduced losses, and a strong cash position. However, concerns arise from reliance on debt financing, competitive pressures, and vague responses in the Q&A about FDA deliverables and DoD contracts. The strong revenue growth and optimistic guidance are offset by uncertainties in operational changes and market competition, leading to a neutral sentiment prediction for stock price movement.
The earnings call presents a mixed picture: strong R&D revenue growth and reduced operating losses are positive, but reliance on debt financing and potential operational challenges pose risks. The Q&A reveals uncertainty around FDA deliverables and DoD contracts, which could concern investors. Despite the optimistic guidance and financial improvements, the lack of clarity and potential risks balance out the positives, resulting in a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
